Ask anything about the Elite II.

The guide cites TGA medicinal cannabis guidance stating that cannabis for medicinal purposes should be vaporised and not smoked. It positions vaporisation as the preferred inhalation method for dried cannabis flower because it avoids combustion and reduces exposure to unwanted combustion byproducts.

Smoking relies on combustion, which can occur at temperatures above 230°C and may expose patients to smoke, carbon monoxide, irritants, and carcinogenic compounds. Vaporisation uses controlled heat, typically around 180°C to 230°C, to release cannabinoids and terpenes without burning the plant material.

The guide explains that smoking can destroy cannabinoids through high heat or lose them in side-stream smoke. Vaporisation can provide more controlled extraction and delivery, supporting more consistent administration and potentially reducing wasted flower material.

Nicotine devices atomise e-liquid containing nicotine, carrier liquids, and permitted flavour compounds. Therapeutic cannabis vaporisers heat dried cannabis flower directly, supporting decarboxylation and vaporisation of cannabinoids and terpenes from plant material. Their chamber design, temperature control, and regulatory pathway are different from nicotine vaporisation products.

The guide groups the benefits into reduced exposure to combustion byproducts, enhanced efficiency and dosage control, rapid onset, customisable effects through temperature selection, more discreet use because of reduced odour, portability, and preservation of flavour and aroma compounds.

The guide discusses chronic pain, spasticity in neuromuscular conditions, nausea, appetite loss and cachexia, sleep disturbance, and anxiety as clinical contexts in which cannabinoids and inhaled delivery may be considered by qualified healthcare professionals. This information is educational and should sit in HCP-oriented areas of the site.

The guide describes therapeutic cannabis vaporisation devices as heating dried flower below combustion, typically between 180°C and 230°C. It also identifies terpene-focused lower ranges beginning around 155°C to 180°C.

Temperature and time affect cannabinoid volatilisation, terpene release, and formation of unwanted breakdown products. Precision control lets clinicians and patients fine-tune the experience while staying below combustion temperatures.

Key cannabinoids occur in the plant as inactive acid forms such as THCA and CBDA. Heat converts these into active forms such as THC and CBD through decarboxylation, which the guide describes as temperature-dependent and commonly optimised around 180°C to 210°C.

Terpenes are aroma compounds in cannabis. The guide notes that more than 200 have been identified, with common examples including myrcene, limonene, pinene, and linalool. Because terpenes are volatile at relatively low temperatures, vaporisation can help preserve flavour and aroma when compared with combustion.

The guide cites research showing that cannabinoid extraction changes by temperature. It notes that at 180°C only a small portion of THC evaporates within the first 20 to 40 seconds, while at 230°C THC volatilisation is higher over the same period. This supports the clinical value of adjustable temperature control.

The guide lists testing and certification work aligned with IEC/EN 60601-1, IEC/EN 60601-1-11, IEC/EN 60601-1-2, IEC/EN 60601-1-6, IEC 62366, IEC 62304, UN 38.3, ISO 10993-5, -10, -18, -23, and ISO 18562-1, -2, -3. It states that all tests passed with no failures.

The guide reports mouthpiece lip-contact temperatures of 40.1°C to 41.3°C and a maximum recorded inhaled vapour temperature of 49.2°C. It also describes an internal safety control that shuts the device down at 53°C internal temperature and allows restart only after the internal temperature drops below 40°C.

The guide describes a dedicated study at 210°C using a custom vaping machine that simulated 500 mL, 5-second inhalations at two inhalations per minute. It measured THC reduction in flower residue and cumulative THC captured in vapour over multiple inhalations.

The study reported cumulative THC captured in vapour above 2.5 mg by 5 inhalations, or 2.5 minutes, and above 5 mg by 10 inhalations, or 5 minutes. It also reported progressive reduction of THC in flower residue, reaching more than 95% reduction by 15 inhalations, or 7.5 minutes.

The guide highlights dual heater technology, patented clean air intake, precise temperature control, ceramic vapour path, easy-open magnetic lid, haptic feedback, a 2100 mAh rechargeable lithium-ion battery, full-colour TFT display, USB-C fast charging, and a compact discreet design.

ARTG-registered devices have undergone TGA medical device assessment for safety, quality, and efficacy and must meet the essential principles for medical devices in Australia. Unregistered devices have not undergone the same ARTG inclusion process and require appropriate access pathways and clinical justification.

The guide lists safety evaluation, manufacturer quality systems, performance assessment, regulatory compliance, labelling and instructions for use, post-market surveillance, and adverse event monitoring as key confidence points for ARTG-approved devices.

The guide states that unregistered devices can only be imported with the appropriate licence and permit, supplied through SAS or Authorised Prescriber pathways, and used where ARTG-included goods are not clinically appropriate for the patient.

The global certification list is: Australia: ARTG Entry 526764, Class IIb medical device; Canada: Health Canada HC MDL 113029; New Zealand: Medsafe NZ WAND registered; Manufacturing: MDSAP, ISO 13485.

The guide recommends introducing vaporisation as an alternative to smoking, explaining the absence of combustion, describing potential benefits such as reduced exposure to harmful byproducts and more precise dosing, and clarifying that medical-grade cannabis vaporisers are different from nicotine vapes.

The guide recommends considering respiratory health, dexterity, cognitive ability to operate the device, treatment goals, and symptom management needs. It also notes that patients with respiratory conditions or allergies should be closely monitored.

The guide emphasises starting with low doses and gradually titrating based on patient response and tolerability. It also suggests considering temperature settings, frequency of use, faster onset, and shorter duration when compared with some other administration methods.

The guide recommends demonstrating correct loading, operation, and cleaning; providing written instructions or reputable online resources; teaching patients to recognise overconsumption or adverse reactions; encouraging open communication; and adjusting treatment as needed.

The guide frames vaporisation as part of a treatment protocol requiring follow-up. Healthcare professionals should monitor adverse effects and outcomes, remain prepared to modify dose, frequency, medicine selection, or administration method, and keep current with new research.

ARTG-registered devices have been assessed by the TGA for safety, efficacy, and quality. Unregistered devices require clinical justification under SAS-B or Authorised Prescriber pathways and are only approved when ARTG-listed devices are unsuitable. Mood State Medical provides ARTG-registered devices so healthcare professionals can access compliant, TGA-approved options that meet Australian standards for medical-grade cannabis administration.

ARTG-registered devices have undergone formal TGA evaluation for safety, quality, and performance, including temperature control, material safety, labelling compliance, manufacturer quality systems, and ongoing post-market monitoring. Registered vaporisers give healthcare professionals and patients confidence that the device meets Australian medical device standards.

Vaporisation avoids combustion and reduces exposure to harmful byproducts such as carbon monoxide and particulate matter. It also offers more precise dosing control and efficient cannabinoid delivery. Medical-grade vaporisers operate within controlled temperature ranges to support therapeutic delivery while minimising toxic byproduct exposure.

Vaporised cannabinoids are rapidly absorbed via the lungs, with peak plasma THC concentrations reported in as little as 3 minutes. This route bypasses first-pass metabolism, supporting faster onset and improved bioavailability compared with some other administration methods.

Most cannabinoids vaporise effectively between 180°C and 230°C, while terpenes begin to volatilise around 155°C to 180°C. Controlled temperature can support compound-specific targeting, and the Elite II allows precise adjustment within its operating range.

Clinicians should consider respiratory health, dexterity, cognitive ability, intended therapeutic goals, and symptom-management needs. Vaporisation may not be suitable for patients with significant respiratory compromise. Device features such as ergonomic form, haptic feedback, magnetic lids, and intuitive displays can support accessibility.

Temperature affects the rate and completeness of cannabinoid extraction. Higher settings can support more complete volatilisation, while lower settings may emphasise terpene-rich profiles and a milder experience. Temperature selection should follow clinical guidance and patient tolerability.

Vaporising heats cannabis enough to release active ingredients like THC and CBD without burning the material. This avoids smoke, ash, and combustion byproducts while still supporting therapeutic delivery when used as prescribed.

No. Medical cannabis vaporisers heat natural dried flower or prescribed cannabis materials rather than atomising nicotine liquids. They are purpose-built for therapeutic cannabis use with controlled heating.

No. Vaporisers typically produce a milder scent that fades more quickly and does not cling like smoke. The Elite II is compact and designed for discreet, low-odour medical use.

Yes. Temperature control can influence vapour density, flavour, and perceived effect. Patients should follow their prescriber’s guidance and adjust only within the recommended use plan.

Many patients feel effects within minutes after inhaling. Vaporisation is a fast-acting administration method because cannabinoids are absorbed through the lungs.

Yes. Vaporising can help preserve terpenes, the compounds that contribute to aroma and flavour. Ceramic chambers and controlled heat can support a clean, consistent vapour pathway.

Therapeutic cannabis vaporisation devices are used as part of a medical treatment plan. Medicinal cannabis itself requires appropriate prescription or authorised access in Australia. The Elite II is intended for prescribed medicinal cannabis use.

Yes, when used medicinally under healthcare professional supervision and in accordance with Australian requirements. Devices should be ARTG-included or accessed through appropriate pathways where clinically justified.

The Grenco Medical Elite II Vaporiser is a certified medical-grade dry herb vaporiser designed for patients using medicinal cannabis for therapeutic purposes. Its global certification list is Australia ARTG Entry 526764, Class IIb medical device; Health Canada HC MDL 113029; Medsafe NZ WAND registered; and MDSAP, ISO 13485 manufacturing certification.

Functionally, yes. The Grenco Medical Elite II Vaporiser uses the same advanced heating technology, form factor, and user interface as the G Pen Elite II. This version is manufactured in a medical-grade facility and is supported by Australia ARTG Entry 526764, Class IIb medical device; Health Canada HC MDL 113029; Medsafe NZ WAND registered; and MDSAP, ISO 13485 manufacturing certification.

The Grenco Medical Elite II Vaporiser is designed exclusively for use with dry medicinal cannabis flower. It is not compatible with concentrates, oils, or liquids.

The supplied kit includes the Grenco Medical Elite II Vaporiser, hemp travel case, protective silicone sleeve, USB-C charging cable, and removable pick tool.

View the box contents photo and full list

Vaporisation heats medicinal cannabis without burning it, releasing active compounds such as THC and CBD in vapour form. This avoids smoke, tar, and ash associated with combustion and supports a more controlled delivery method for medical use.

The Grenco Medical Elite II Vaporiser is produced under MDSAP and ISO 13485 manufacturing certification. Units undergo testing for safety, performance, and consistency.

The device certifications listed for the Grenco Medical Elite II are: Australia: ARTG Entry 526764, Class IIb medical device; Canada: Health Canada HC MDL 113029; New Zealand: Medsafe NZ WAND registered; Manufacturing: MDSAP, ISO 13485.

The device allows temperature control between 200°F and 430°F (93°C to 221°C), giving patients the ability to adjust vapour density and overall experience based on personal needs or clinician guidance.

Regular cleaning helps maintain performance. Use the included cleaning brush to remove debris from the chamber, gently clean the mouthpiece and airpath with isopropyl alcohol and cotton swabs, and never submerge any part of the device in liquid. Refer to the Instructions for Use for full cleaning instructions.

Yes. The Support page includes short owner video guides for using the Elite II and cleaning the device. These videos are intended to support, not replace, the Instructions for Use.

Open the getting started guide

Allow approximately 30 seconds after it vibrates for the flower to heat, then the device is ready to use.

Open the first-session steps

A full charge provides multiple sessions depending on temperature and duration. The device features USB-C charging and a high-capacity lithium-ion battery for daily use.

The Grenco Medical Elite II Vaporiser is portable and discreet. Always check local laws regarding medicinal cannabis and vaporiser use, especially when flying or crossing borders.

Visit the product registration page, enter your serial number and purchase information, and your warranty will be activated. Registration also helps support future updates and support access.

Open product registration

The support team can assist with device troubleshooting, replacement parts, authorized clinic or distributor information, and medical-use guidance in coordination with the patient's healthcare provider.

Open support

Vaporisation gently heats dried medicinal cannabis flower to a temperature that activates key therapeutic compounds, such as THC and CBD, without combustion. This avoids inhalation of combustion byproducts such as smoke, ash, or carcinogenic toxins while still delivering plant compounds as vapour.

The Grenco Medical Elite II Vaporiser is purpose-built to support this medically preferred method of administration, delivering consistent vapour with each session.

No. Medicinal cannabis vaporisers are different from nicotine e-cigarettes. Nicotine vapes atomise liquid, while medicinal cannabis vaporisers heat solid plant material to release active ingredients without burning it.

The Grenco Medical Elite II Vaporiser is specifically designed for dried medicinal cannabis flower, offering precise temperature control for therapeutic use under medical supervision.

Vaporisation typically creates a milder aroma than smoking. Because there is no combustion, the scent is subtler, dissipates more quickly, and is less likely to cling to clothing or surroundings.

The Grenco Medical Elite II Vaporiser is designed to offer a low-odour experience for discretion at home or in approved healthcare settings.

Adjustable temperature settings allow patients and clinicians to tailor the experience, from lighter vapour at lower temperatures to more robust effects at higher settings. Treatment plans and dose guidance should always come from the prescribing healthcare practitioner.

Vaporised cannabinoids are absorbed through the lungs, and patients may feel effects quickly. Individual timing varies by patient, medicine, temperature, dose, and clinical plan. Follow the advice of the prescribing healthcare practitioner.

Unlike combustion, vaporisation can preserve terpenes responsible for the aroma and taste of medicinal cannabis. The Grenco Medical Elite II Vaporiser uses a ceramic heating chamber intended to support a smooth session.

Therapeutic medicinal cannabis vaporisers should be used as part of a prescribed treatment plan under the Special Access Scheme (SAS) or Authorised Prescriber (AP) pathways where applicable. Associated medicinal cannabis must be legally prescribed by a healthcare professional.

The global certification list is: Australia: ARTG Entry 526764, Class IIb medical device; Canada: Health Canada HC MDL 113029; New Zealand: Medsafe NZ WAND registered; Manufacturing: MDSAP, ISO 13485.

Use must occur legally and under medical supervision. Devices must be registered on the Australian Register of Therapeutic Goods (ARTG) or accessed through approved pathways with appropriate clinical justification.

The Grenco Medical Elite II Vaporiser certification list is: Australia: ARTG Entry 526764, Class IIb medical device; Canada: Health Canada HC MDL 113029; New Zealand: Medsafe NZ WAND registered; Manufacturing: MDSAP, ISO 13485.

Medically approved devices are reviewed for safety, efficacy, and quality. Unregistered devices generally require justification through pathways such as the Special Access Scheme (SAS-B) or Authorised Prescriber (AP) programs and are typically used when medically approved alternatives are unsuitable.

The Grenco Medical Elite II Vaporiser is a medically approved device, giving clinicians and patients confidence that it meets medical standards for medicinal cannabis administration.

Medically approved devices such as the Grenco Medical Elite II Vaporiser have passed formal evaluation for compliance with temperature regulation, materials safety, labelling standards, and manufacturer quality assurance. These devices are also subject to ongoing post-market surveillance.

Vaporisation avoids combustion, reducing patient exposure to combustion byproducts such as carbon monoxide and carcinogenic particulates. It can also allow more controlled dosing and improved cannabinoid bioavailability.

The Grenco Medical Elite II Vaporiser supports this harm-reduction model by delivering cannabinoids at precise temperatures.

Vaporised cannabinoids are absorbed through the lungs, which can result in faster onset and improved bioavailability compared with oral ingestion because the route bypasses first-pass metabolism in the liver. Patient response varies and should be interpreted within the clinical treatment plan.

Cannabinoids vaporise effectively between 180°C and 230°C, while many terpenes begin to volatilise around 155°C to 180°C. Temperature precision can help clinicians tailor the therapeutic experience to individual treatment plans.

The Grenco Medical Elite II Vaporiser offers precise, adjustable temperature control within this clinical range.

Assessment should consider the patient's respiratory health, cognitive function, dexterity, and therapeutic goals. Vaporisation may be contraindicated in patients with severe respiratory conditions.

The Grenco Medical Elite II Vaporiser includes intuitive controls, tactile feedback, ergonomic handling, and a magnetic mouthpiece to support patient usability.

Higher vaporisation temperatures, up to 230°C, can facilitate rapid cannabinoid extraction. Lower temperatures may preserve more volatile terpenes, delivering a milder and more nuanced effect profile.

The Grenco Medical Elite II Vaporiser is calibrated for consistent performance across this range.